•                                                                                         
    • Overview
    • The History
    • Leadership Team
      • William C. Weldon
      • Robert A. Ingram
      • Christopher A. Viehbacher
      • H. Edward Hanway
      • Martin J. Murphy
      • Gregory A. Curt
      • Mace Rothenberg
      • Judy O'Hagan
      • John N. Dornan
    • Task Forces at a Glance
    • Vendor Endorsement Policy
    • FAQs
       
  •                                             
    • News
    • Press Releases
    • Videos
       



Martin J. Murphy

Chief Executive Officer, CEO Roundtable on Cancer
Chairman of the Board and Chief Executive Officer, AlphaMed Consulting

MurphyM.JPG Dr. Martin J. Murphy, Jr. brings four decades of healthcare and cancer research experience to his CEO Roundtable role through his extensive work as a peer-reviewed cancer scientist, professor of medicine, editor and oncology consultant. Dr. Murphy, a graduate of New York University, was awarded postdoctoral fellowships at the Institut de Pathologie Cellulaire (Paris, France), the Patterson Laboratories of the Christie Hospital and Holt Radium Institute (Manchester, UK), and the John Curtin School of Medical Research, Australian National University (Canberra, Australia).  He was on the faculty of St. Jude Children's Research Hospital (Memphis, TN), Memorial Sloan-Kettering Cancer Center (New York, NY), and Wright State University School of Medicine (Dayton, OH).   Dr. Murphy founded the Hipple Cancer Research Center in 1977 and led it for the next two decades as its chief executive officer.  When he retired from Hipple, endeavoring to advance both new discoveries and enhance improved global healthcare delivery, Dr. Murphy founded AlphaMed Consulting that provides support for comprehensive cancer centers as well as selected research-intensive pharmaceutical and biotech companies.

Dr. Murphy is a director of Jennerex Biotherapeutics, a clinical-stage biotech company developing novel viral therapy for cancers.  He is also a director of Aldagen, a clinical-stage regenerative medicine company. He is a member of the Scientific Advisory Board ( Dr. Herb Boyer, chairman) of Hatteras Venture Partners, a charter member of the Scientific Advisory Board of Pappas Ventures,  (2002-2008), and the primary biopharma consultant to Catellus, the developer of Mission Bay, the largest life science campus in San Francisco. He was the charter chairman of the Scientific Advisory Board of ALMAC Diagnostics (2000-2008); a founding member of Queen’s University School of Medicine International Review Board, chairman of The ASCO Cancer Foundation, a founding director of the All-Ireland Cancer Foundation, and a director of the American Cancer Society Foundation (2000-2009).  He is a director of the Foundation for the National Institutes of Health (Dr. Charles Sanders, chairman), a member of the Board of Visitors of the UNC Lineberger Comprehensive Cancer Center, member of the Board of Advisors of the H. Lee Moffitt Cancer Center & Research Institute, and a charter member and director of C-Change, co-chaired by former President George H. W. Bush and former First Lady Barbara Bush; U.S. Senator Dianne Feinstein serves as vice chair. Queen’s University School of Medicine (Belfast)conferred upon him the Doctor of Medical Science degree.

Dr. Murphy is founding chief executive officer of the CEO Roundtable on Cancer, established in 2001 at the request of former President George H.W. Bush.  He and Ann (nee Flesher) Murphy, PhD, were married in 1965; they have five children and ten grandchildren.

 

 

July 29 2010
Blue Cross Blue Shield of North Carolina awarded CEO Cancer Gold StandardTM accreditation

CARY, NC (July 29, 2010) – Blue Cross and Blue Shield of North Carolina (BCBSNC) has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.
Read More

June 21 2010
Publicis awarded CEO Cancer Gold StandardTM accreditation

CARY, NC (June 21, 2010) – Publicis Healthcare Communications Group (PHCG), the world's largest healthcare communications group, has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.
Read More

January 21 2010
The CEO Roundtable on Cancer Salutes SAS and Meridian Health

The CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard, salutes SAS Institute for being ranked No.1 on FORTUNE magazine’s annual “100 Best Companies to Work For” list.
Read More

Contact Us
Privacy Policy
Terms Of Use
Technical Support
Site Map
Copyright 2010
Print Page Email Page to Friend Feedback